New analysis suggests survival advantage with one AAV drug

Pooled results favored rituximab, particularly in studies with mostly GPA patients

Written by Patricia Inacio, PhD |

A man relaxing in a reclining chair with an IV line attached to his arm, holding a blue mug, while another person sits in the background.

A new analysis suggests that rituximab may offer a one-year survival advantage over cyclophosphamide for people with ANCA-associated vasculitis (AAV). (Photo from iStock)

An analysis of published studies found lower one-year death rates with rituximab than with cyclophosphamide among people with ANCA-associated vasculitis (AAV).

The findings suggest a possible survival advantage with rituximab. This pattern was particularly evident in studies involving patients with lower disease activity at diagnosis or in which most participants had granulomatosis with polyangiitis (GPA), the most common type of AAV.

The study, “Cyclophosphamide vs rituximab induction therapy for ANCA-associated vasculitis. A systematic review and meta-analysis of 12-month mortality,” was published in Seminars in Arthritis and Rheumatism.

Recommended Reading
A hand holding a blue marker writes “Clinical Trials” on a yellow sticky note beside a stethoscope.

New cell therapy shows encouraging safety in autoimmune diseases

Treatment options for ANCA-associated vasculitis

AAV is a group of autoimmune diseases in which the immune system mistakenly attacks small blood vessels, causing inflammation and potentially damaging organs, especially the kidneys and lungs. Its main types include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).

Although advances in treatment have improved survival, people with AAV remain at increased risk of death, particularly from uncontrolled disease and infections.

Treatment typically begins with induction therapy, which aims to bring the disease into remission, a period of little to no disease activity. Induction therapy often combines glucocorticoids with immunosuppressive medications, such as cyclophosphamide or rituximab.

Cyclophosphamide has long been used to treat severe AAV but is linked to an increased risk of infections, infertility, and certain cancers. Rituximab targets B cells, immune cells involved in the abnormal immune response that drives AAV. It is marketed as Rituxan in the U.S. and MabThera in Europe and is also available as biosimilars.

“Whilst the choice of induction therapy in AAV is known to contribute to risk of disease relapse, the impact of induction therapy on mortality rate in AAV is less clear,” the researchers wrote. “The difference in mortality between induction therapy with cyclophosphamide and rituximab has not been determined.”

To investigate, researchers in New Zealand and Australia systematically reviewed published studies that reported death rates within 12 months of starting cyclophosphamide or rituximab induction therapy in adults with AAV.

Review compares one-year death rates across AAV treatments

The final analysis included 48 studies: 15 randomized controlled trials, five prospective studies that followed patients over time, and 28 retrospective studies that analyzed previously collected data.

The studies included 5,050 patients, including 3,553 who received cyclophosphamide and 1,183 who received rituximab to induce remission.

Among the patients, about one-third (34.2%) had GPA, about one-quarter (26.1%) had MPA, and 3% had EGPA, based on available data. Patients in most studies also received glucocorticoids during induction therapy.

When researchers combined the study results, the estimated death rate within one year was 10.7% among patients treated with cyclophosphamide, compared with 5.9% among those receiving rituximab. The difference was statistically significant, favoring rituximab.

However, in the five studies that directly compared the two medications, cyclophosphamide showed a small survival advantage that was not statistically significant.

The researchers did not have enough data to directly compare one-year death rates among the different types of AAV. However, further sensitivity analyses found that rituximab was associated with significantly lower one-year death rates in studies where most participants had GPA.

Survival findings vary by disease activity and patient groups

In studies involving patients with lower disease activity at diagnosis, one-year death rates were also significantly lower with rituximab than with cyclophosphamide.

Differences in death rates also favored rituximab in analyses considering older patients, studies with mostly men, and studies published since 2005. However, none of these differences was statistically significant, meaning they could be due to chance.

The researchers acknowledged several limitations. Most evidence came from retrospective studies, which are more susceptible to patient selection bias. Patients receiving rituximab also tended to be older and more likely to be women than those receiving cyclophosphamide.

The researchers wrote, “The findings of the systemic literature review favour the use of rituximab for AAV induction therapy in 12-month mortality outcome when compared to cyclophosphamide, particularly for the treatment of GPA.” They added, “Further randomised trial data is required to directly compare cyclophosphamide and rituximab for the induction treatment of AAV, specifically for the remission of GPA.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.